Emulsi Biotech Secures a Pre-Seed Funding to Advance Novel Oral Drug Delivery Technology for Biological Drugs
Eimantas Gladkauskas, CEO of Emulsi Biotech
LUND, SWEDEN – Emulsi Biotech, a pioneering life science company specializing in technology for advanced drug delivery, today announced the successful closing of a 7 million SEK pre-seed funding round. The investment round was led by BSV Ventures, with active participation from Almi Invest and two prominent angel investors.
Oral drug delivery remains the holy grail for biological drugs, which are traditionally restricted to injections due to poor bioavailability and harsh gastrointestinal environments. Emulsi Biotech’s proprietary lipid-based technology aims to overcome these historical barriers, offering a non-invasive, patient-friendly alternative
The newly secured capital will be primarily deployed to validate Emulsi Biotech’s novel oral drug delivery platform through in vivo studies. This critical milestone aims to demonstrate the technology's efficacy and safety, paving the way for future clinical development and transforming how complex biological therapies are administered.
"Emulsi Biotech is tackling one of few pharma’s most persistent challenges - effective oral drug delivery - with their developed technology, and at BSV Ventures we're proud to support the team as they scale this science to market." - BSV Ventures
"Securing our first venture capital round is a massive achievement, but it also comes with a great responsibility. We are incredibly excited to bring Emulsi Biotech one step closer to the market, and this pre-seed round is a monumental first step towards achieving that vision." - Eimantas Gladkauskas, CEO and Co-founder of Emulsi Biotech
”Eimantas has made an impressive transition from researcher to CEO, combining scientific excellence with strong leadership. Emulsi's technology has the potential to solve one of the pharmaceutical industry's biggest challenges. The benefits could be significant for both patients, who may gain easier access to treatments, and drug developers, who could achieve the same therapeutic effect with lower doses." - Thomas Areschoug, Business Development Coach at SmiLe Venture Hub.
With the successful completion of this round, Emulsi Biotech is poised to accelerate its laboratory operations in Lund's world-class biotechnology ecosystem and expand its research capabilities ahead of the upcoming in vivo trials.
For more information, please contact:
Eimantas Gladkauskas, CEO and Co-founder of Emulsi Biotech,
eg@emulsibiotech.com
or
Kush Punyani, CBO and Business coach, SmiLe Venture Hub, kushagr.punyani@smileventurehub.com
About Emulsi Biotech
Founded in late 2023 as a spin-off from the prestigious Lund University, Division of Biotechnology, Emulsi Biotech was established by a team of three co-founders, Eimantas Gladkauskas, Cecilia Tullberg and Professor Patrick Adlercreutz. Headquartered in Lund, Sweden, the company leverages the region's premier life science infrastructure to tackle complex physical chemistry and formulation challenges. Emulsi Biotech focuses on developing proprietary, patient-friendly lipid mixtures designed to handle the solubilization and oral delivery of biological drugs.
Emulsi Biotech is a member of SmiLe Venture Hub.
Read post on SmiLe Venture Hub – Pioneering Life Science and Foodtech Innovations newsroomVisit SmiLe Venture Hub – Pioneering Life Science and Foodtech Innovations newsroom
About SmiLe newsroom
SmiLe is a leading venture hub that specializes in advancing life science and foodtech startups from concept to commercialization. We offer comprehensive support through every stage of entrepreneurship, including tailored incubation and acceleration programs, a variety of educational courses, and access to top-tier lab facilities. To date, our flagship incubator program has supported over 120 startups, facilitating their collective acquisition of more than EUR 1.22 billion in venture capital and contributing to 21 successful IPOs. Recognized as one of Europe’s leading startup hubs in 2024 by the Financial Times and Statista, SmiLe continues to be a catalyst for innovation in the life sciences sector. As a non-profit entity based in Lund, Sweden, SmiLe is supported by Region Skåne, Lund Municipality, Lund University, and Medicon Village. We are also backed by our partners Agilent, Sparbanken Skåne, Høiberg, Setterwalls, Zacco, Key2Compliance, Phase Holographic Imaging, ChemoMetec, Samplix, Qiagen, Bio-Rad, Zeiss, SmartStone Nordics, Säkra, Servier and AbbVie Scandinavia. For more information: www.smileventurehub.com